457 related articles for article (PubMed ID: 22674214)
1. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M; Schalken JA
J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
[TBL] [Abstract][Full Text] [Related]
3. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
4. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
Urologiia; 2015; (5):46-50. PubMed ID: 26859937
[TBL] [Abstract][Full Text] [Related]
5. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
6. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
[TBL] [Abstract][Full Text] [Related]
7. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
10. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
[TBL] [Abstract][Full Text] [Related]
13. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
14. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
16. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
Floriano-Sánchez E; Cárdenas-Rodríguez N; Castro-Marín M; Alvarez-Grave P; Lara-Padilla E
Clin Invest Med; 2009 Dec; 32(6):E258. PubMed ID: 20003831
[TBL] [Abstract][Full Text] [Related]
17. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
18. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
19. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
